

Nevada Medicaid

Submit fax request to: 855-455-3303

Please note: All information below is required to process this request.

Somavert® (pegvisomant) Prior Authorization Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED.

Member Information (required)				Provider Information (required)				
Member Name:				Provider Name:				
Insurance ID#:				NPI#:	Specialty:	Specialty:		
Date of Birth:				Office Phone:				
Street Address:				Office Fax:				
City: State: Zip:			Zip:	Office Street Address:				
Phone:			1	City:	State:	Zip:		
Medication Information (required)								
Medication Name:			Strength:	Dosage Form:				
 Check if requesting brand Check if request is for initial certification (12 weeks) Check if request is for recertification of therapy (12 months) 				Directions for Use:				
Clinical Information (required)								
Provide Diagnosis:								
	Diagnosis of acromegaly.							
	Other diagnosis:			ICD-10 Code(s):				
Drug-Specific Information (required)								
Inadequate response or not a candidate for (mark all that apply): Surgery								
	□ Radiation Therapy							
	□ Dopamine agonist therapy							
	Trial and failure or contraindication or intolerance to generic octreotide.							
	Prescribed by or in consultation with an endocrinologist.							
	For recertification, please provide documentation of positive clinical response to Somavert® therapy such as biochemical control; decrease or normalization of IGF-1 levels.							

Attach any additional comments, diagnoses, symptoms, medications tried or failed, or other information the physician feels is important to this review.

<u>Please note:</u> This request may be denied unless all required information is received. For urgent or expedited requests please call 1-800-711-4555. This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

FA-182 11/30/2020 Page 1 of 1